Arvinas (NASDAQ:ARVN) Posts Quarterly Earnings Results, Beats Estimates By $2.95 EPS

Arvinas (NASDAQ:ARVN) released its earnings results on Tuesday. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of ($0.37) by $2.95, FiscalAI reports. The business had revenue of $249.70 million during the quarter, compared to analysts’ expectations of $60.71 million. Arvinas had a negative net margin of 247.54% and a negative return on equity of 44.38%. The firm’s revenue was up 1014.7% on a year-over-year basis. During the same period last year, the business earned ($0.84) earnings per share.

Here are the key takeaways from Arvinas’ conference call:

• VEPPANU was approved by the FDA as the first PROTAC degrader and licensed to Rigel, which is expected to make the drug available soon. The deal and approval generated substantial Q2 revenue, including a $50 million Pfizer milestone and $62.5 million in license revenue.
• Arvinas expects multiple clinical catalysts, including initial ARV-393 BCL-6 degrader data by year-end 2026, ARV-027 muscle-exposure and degradation data in the first half of 2027, and additional ARV-102 biomarker data in October.
• ARV-393 enrollment accelerated near predicted efficacious dose levels, but most 2026 data will come from earlier, likely subtherapeutic cohorts and include an unusually high proportion of T-cell lymphoma patients. More mature monotherapy and glofitamab-combination data, including DLBCL patients, are planned for 2027.
• Regulatory requests have pushed the start of ARV-102 trials in PSP from 2026 into 2027, delaying the program’s planned phase I-B and registrational-oriented studies.
• The company reported $567.9 million in cash, cash equivalents, and marketable securities and reiterated that its cash runway extends into the second half of 2028, supporting continued investment in its early-stage oncology and neurology pipeline.

Arvinas Price Performance

Shares of NASDAQ ARVN opened at $9.29 on Tuesday. The stock’s fifty day moving average price is $8.07 and its two-hundred day moving average price is $10.32. Arvinas has a one year low of $6.05 and a one year high of $14.51. The firm has a market cap of $599.58 million, a price-to-earnings ratio of -2.78 and a beta of 1.71.

Analysts Set New Price Targets

ARVN has been the subject of a number of recent analyst reports. Zacks Research upgraded shares of Arvinas from a “strong sell” rating to a “hold” rating in a research note on Tuesday, May 26th. Weiss Ratings lowered shares of Arvinas from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday. Citigroup upped their target price on shares of Arvinas from $21.00 to $24.00 and gave the company a “buy” rating in a report on Monday, May 4th. BTIG Research raised their target price on shares of Arvinas from $16.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, May 13th. Finally, Stephens reiterated an “overweight” rating and set a $18.00 price target on shares of Arvinas in a report on Wednesday, June 3rd. Eight research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $15.42.

Insider Transactions at Arvinas

In other Arvinas news, CEO Randy Teel sold 9,657 shares of Arvinas stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $9.94, for a total value of $95,990.58. Following the completion of the sale, the chief executive officer owned 287,218 shares in the company, valued at $2,854,946.92. The trade was a 3.25% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Andrew Saik sold 5,696 shares of the business’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $8.16, for a total transaction of $46,479.36. Following the completion of the sale, the chief financial officer directly owned 187,432 shares of the company’s stock, valued at $1,529,445.12. This represents a 2.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 41,728 shares of company stock valued at $402,649. 7.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Arvinas

A number of hedge funds and other institutional investors have recently made changes to their positions in ARVN. Tower Research Capital LLC TRC grew its position in Arvinas by 491.4% during the second quarter. Tower Research Capital LLC TRC now owns 5,819 shares of the company’s stock worth $43,000 after buying an additional 4,835 shares in the last quarter. Canada Pension Plan Investment Board lifted its position in shares of Arvinas by 109.4% during the 2nd quarter. Canada Pension Plan Investment Board now owns 6,700 shares of the company’s stock valued at $49,000 after acquiring an additional 3,500 shares during the period. Jain Global LLC bought a new stake in shares of Arvinas during the 3rd quarter valued at $95,000. Oxford Asset Management LLP increased its position in shares of Arvinas by 15.5% in the second quarter. Oxford Asset Management LLP now owns 16,705 shares of the company’s stock worth $123,000 after purchasing an additional 2,242 shares during the period. Finally, Virtu Financial LLC acquired a new position in Arvinas in the third quarter valued at about $124,000. 95.19% of the stock is currently owned by institutional investors and hedge funds.

Arvinas Company Profile

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.